This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
News|Articles|May 2, 2014
- Pharmaceutical Technology-05-02-2014
- Volume 38
- Issue 5
Laser Diffraction Software Supports Analytical QbD
Author(s)Melanie Sena
Laser Diffraction Software Supports Analytical QbD
A software upgrade for the Mastersizer 3000 laser diffraction particle size analyzer from Malvern Instruments decreases the analytical workload associated with developing and validating particle sizing methods. New operational features, such as an Optical Property Optimizer (OPO ), simplify the process of method development. The new OPO tool enables the identification of appropriate refractive index and absorption values for the analysis of any given sample. It also allows analysts to research the impact of optical properties on reported particle size, in real time, using an intuitive point-and-click tool. According to the company, this helps exploration of the operating space in which robust measurements are assured, to define the method operable design region for a particle size analysis method.
Articles in this issue
over 12 years ago
Extractables and Leachables Testingover 12 years ago
Mass Spectrometer Enhances Performance in Protein Analysisover 12 years ago
Data Integrity in the Analytical Laboratoryover 12 years ago
Q&A with Tony Mitchell, Pharma Tech Industriesover 12 years ago
Linking Drug Shortages and Quality Metricsover 12 years ago
EU Steps Up Inspection Effortsover 12 years ago
Aggregation System Improves Analysis of Sub-Visible Particlesover 12 years ago
Boosting New Antibiotic Drug Development in Europeover 12 years ago
Freeze Drying Protein FormulationsRelated to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.